•
Mar 31, 2021

Cloudflare Q1 2021 Earnings Report

Cloudflare experienced record revenue growth and customer acquisition.

Key Takeaways

Cloudflare announced strong Q1 2021 financial results, with revenue up 51% year-over-year and record dollar-based net retention of 123%. The company also saw strong growth in large customers, which now represent more than half of total revenue.

Revenue totaled $138.1 million, a 51% year-over-year increase.

Dollar-based net retention reached a record 123%, up 600 basis points year-over-year.

GAAP gross profit was $106.0 million, with a gross margin of 76.8%.

Free cash flow was negative $2.2 million, representing 2% of total revenue.

Total Revenue
$138M
Previous year: $91.3M
+51.3%
EPS
-$0.03
Previous year: -$0.04
-25.0%
Gross Margin
76.8%
Previous year: 77.2%
-0.5%
Free Cash Flow Margin
-2%
Previous year: -34%
-94.1%
Gross Profit
$106M
Previous year: $70.4M
+50.5%
Cash and Equivalents
$187M
Previous year: $109M
+71.9%
Free Cash Flow
-$2.22M
Previous year: -$30.6M
-92.7%
Total Assets
$1.41B
Previous year: $859M
+63.7%

Cloudflare

Cloudflare

Forward Guidance

For Q2 2021, Cloudflare expects revenue between $145.5 to $146.5 million and a non-GAAP loss per share of $0.04 to $0.03. For the full year 2021, the company anticipates revenue of $612 to $616 million and a non-GAAP loss per share of $0.11 to $0.10.

Positive Outlook

  • Total revenue of $145.5 to $146.5 million for Q2 2021.
  • Full year 2021 total revenue of $612 to $616 million.
  • Q2 2021 Non-GAAP loss from operations of $10 to $9 million.
  • Full year 2021 Non-GAAP loss from operations of $28 to $24 million.
  • Non-GAAP net loss per share of $0.04 to $0.03 for Q2 2021.

Challenges Ahead

  • Substantial uncertainty due to the ongoing COVID-19 pandemic.
  • Impact of the pandemic on operations is estimated as of May 6, 2021.
  • Estimates are highly dependent on numerous factors that may not be predictable or controllable.
  • The timing of administering COVID-19 vaccines around the world and the long-term efficiency of these vaccines.
  • Non-GAAP net loss per share of $0.11 to $0.10 for full year 2021.